A systematic review highlighted the role of haemodialysis in treatment of Diabetic kidney disease (DKD). 

The study aimed to determine the effect of hemodialysis compared to conventional medicine in adult with DKD.

Conference proceedings, and databases such as EMBASE, CNKI, Science Direct, Chinese Biomedical Database, Cochrane Library, Wanfang and VIP were searched from January 2010 to 30 March 2025. For including the patient with DKD, randomized controlled trials comparing hemodialysis plus standard therapy with standard therapy was used. Records were screened and data were extracted. By using Cochrane Handbook 5.3 tool risk of bias was assessed. 

Reduction in parathyroid hormone (MD =  − 37.30, 95% CI − 43.16 to − 31.43; I2 = 0%), interleukin-4 (MD =  − 20.42, 95% CI − 25.89 to − 14.94; I2 = 42%), tumor necrosis factor-α (MD =  − 15.29, 95% CI − 25.05 to − 5.53; I2 = 89%), and interleukin-8 (MD =  − 13.56, 95% CI − 20.85 to − 6.27; I2 = 76%) was seen by hemodialysis compared to control. Despite high heterogeneity (I2 ≥ 99%) reduction in Serum creatinine (MD =  − 1.03, 95% CI − 1.69 to − 0.36) and blood urea nitrogen (MD =  − 0.94, 95% CI − 1.49 to − 0.39). While improvement in Glycemic indices (HbA₁c MD =  − 0.63, 95% CI − 1.34 to 0.08 and fasting glucose MD =  − 0.80, 95% CI − 1.59 to − 0.02) was also observed. No significant difference in overall adverse events was found, however complications were reported in 4 studies.